

CLAIMS

1. A method of treating a disorder, the method comprising administering to a patient in need of treatment for said disorder:

a) an effective dose of relacorilant; and

b) an effective dose of a therapeutic agent, wherein said therapeutic agent is a substrate for CYP2C8 enzyme metabolism, said therapeutic agent having a single agent dose when administered without other pharmaceutical agents, wherein said therapeutic agent effective dose is substantially the same as said single agent dose;

Wherein a) and b) are performed at times effective to provide the patient with an effective level of relacorilant and an effective level of the therapeutic agent at the same time,

Whereby the disorder is treated.

2. The method of claim 1, wherein the relacorilant dose is between about 1 milligram per kilogram (mg/kg) and about 20 mg/kg.

3. The method of claim 1, wherein the relacorilant dose is between about 50 mg and about 500 mg.

4. The method of claim 4, wherein the relacorilant dose is administered at a time within about 15 minutes of the time of administration of the therapeutic agent dose.

5. The method of claim 1, wherein the relacorilant dose and therapeutic agent dose are administered sequentially.

6. The method of claim 5, wherein the relacorilant dose is administered to the patient, and then, after a time interval, the therapeutic agent dose is administered to the patient.

7. The method of claim 5, wherein the therapeutic agent dose is administered to the patient, and then, after a time interval, the relacorilant dose is administered to the patient.

8. The method of claim 6, wherein said time interval is selected from about one hour and about one day.

9. The method of claim 7, wherein said time interval is selected from about one hour and about one day.

10. The method of claim 1, wherein the therapeutic agent is selected from rosiglitazone, pioglitazone, and enzalutamide.
11. The method of claim 1, wherein said disorder is cancer.
12. The method of claim 11, wherein said disorder is prostate cancer.
13. The method of claim 12, wherein the therapeutic agent is enzalutamide.
14. The method of claim 1, wherein said disorder is hypercortisolism.
15. The method of claim 14, wherein the therapeutic agent is selected from rosiglitazone and pioglitazone.
16. A method of treating cancer, the method comprising administering to a patient in need of cancer treatment:
 - a) relacorilant, and
 - b) an anticancer agent, wherein said anticancer agent is a substrate for CYP2C8 enzymes, the anticancer agent having a therapeutic dose when it is administered to a subject in the absence of other pharmaceutical agents, and wherein said anticancer agent is administered to the patient at a dose that is substantially the same as said therapeutic dose.
17. The method of claim 16, wherein said relacorilant is administered to said patient at a dosage of between about 1 milligram per kilogram (mg/kg) and about 20 mg/kg.
18. The method of claim 16, wherein said relacorilant is administered to said patient at a dose of between about 75 mg and about 200 mg per day.
19. The method of claim 16, wherein said relacorilant and said anticancer agent are administered to the patient at substantially the same time.
20. The method of claim 16, wherein said relacorilant and said anticancer agent are administered sequentially to the patient.
21. The method of claim 20, wherein said anticancer agent is administered to the patient, and then, after a time interval, said relacorilant is administered to the patient.
22. The method of claim 20, wherein said relacorilant is administered to the patient, and then, after a time interval, said anticancer agent is administered to the patient.
23. The method of claim 21, wherein said time interval is selected from about one hour and about one day.

24. The method of claim 22, wherein said time interval is selected from about one hour and about one day.

25. The concomitant use of relacorilant and a CYP2C8 substrate in the treatment of a disorder, wherein CYP2C8 substrate alone has been used in treating said disorder, wherein the amount of said CYP2C8 substrate used in said concomitant treatment with relacorilant is the same amount of CYP2C8 substrate as used alone in treating said disorder.

26. The use of claim 25, wherein the amount of relacorilant is between about 50 mg and about 1500 mg.

27. The use of claim 25, wherein the CYP2C8 substrate is selected from rosiglitazone, pioglitazone, and enzalutamide.

28. The use of claim 25, wherein said disorder is cancer.

29. The use of claim 28, wherein said disorder is prostate cancer, and wherein the CYP2C8 substrate is enzalutamide.

30. The use of claim 27, wherein said disorder is hypercortisolism, and wherein the CYP2C8 substrate is selected from rosiglitazone and pioglitazone.